



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jean-Luc BALLIGAND et al.

Serial No.: 10/068,965

Group Art Unit: 1646

Filed: February 11, 2002

Examiner: Unassigned

For: NOVEL PHARMACEUTICAL COMPOSITIONS FOR MODULATING
ANGIOGENESIS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents
Washington, D. C. 20231

I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class
Mail in an envelope addressed to:
Assistant Commissioner For Patents,
Washington, D.C. 20231-0001

Sir:

Name: James E. Grier
Signature: James E. Grier
Date: July 18, 2002

CITED MATERIALS

Applicant(s) hereby disclose the information listed in the attached form PTO-1449.

- ☐ Copies of materials listed but not attached were cited in parent application Serial No. ____; see 37 C.F.R. § 1.98(d).
- ☐ Copies of materials listed but not attached were cited in an International Search Report dated ____; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed ____.

ADDITIONAL INFORMATION

LANGUAGE

- ☒ All listed materials are in the English language; see 37 C.F.R. § 1.98.
- ☐ Non-English language references:
- ☐ The reference(s) _____ in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): _____, respectively.

11. A commercial English language abstract of reference(s) cited in 10 and 12 are provided.

12. An English language search report or a translation of a search report of the counterpart foreign application is provided indicating the relevance of the cited reference(s).

FEES

- ☒ No fee is required for this Information Disclosure Statement because:
 - ☐ This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
 - ☒ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
 - ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
 - ☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
- ☐ A fee is required for this Information Disclosure Statement:
 - ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in § 1.17(p).
 - ☐ This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.


CERTIFICATION

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$ _____. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,




Anthony J. Zelano, Reg. No.: 27,969
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: DCLERC-2P1

Date: July 18, 2002
AJZ:jr

I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class
Mail in an envelope addressed to:
Assistant Commissioner For Patents
Washington, D.C. 20231 on July 18, 2002
Name: James C. Niles
Signature: James C. Niles
Date: July 18, 2002




Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Application Number				10/068,965	
Filing Date				February 11, 2002	
First Named Inventor				Jean-Luc BALLIGAND et al.	
Group Art Unit				1646	
Examiner Name				Unassigned	
Attorney Docket Number				DCLERC-2P1	

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Comments on the amount of the fee are required to complete this form and should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign ☐ in this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known			
		Application Number	10/068,965		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	February 11, 2002		
		First Named Inventor	Jean-Luc BALLIGAND et al.		
		Group Art Unit	1646		
		Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	DCLERC-2P1

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	John R. BURNETT et al., "Inhibition of ACAT by Avasimibe decreases both VLDL and LDL Apolipoprotein B production in Miniature Pigs", Journal of Lipid Research, Vol. 40, No. 7, pp. 1317-1327, July 1999, XP-002156497.	
	2	Jun LIU et al., "Angiogenesis activators and inhibitors differentially regulate Caveolin-1 expression and Caveolae Formation...", The Journal of Biological Chemistry, Vol. 274, No. 22, pp. 15781-15785, May 28, 1999, XP-002156496.	
	3	O. FERON et al., "High LDL-cholesterol Decreases NO Production through Enhanced Caveolin Abundance..." Annual Meeting of the Professional Research Scientists for Experimental Biology, 99, Washington, DC, April 1999, XP-002136666.	
	4	D. KONG et al., "The Anti-Angiogenic Effects of HMGCOA Reductase Inhibitors: A New Role for RHOA GTPASE In the Regulation of Angiogenesis", American Heart Association, vol. 110, No. 18, Dallas TX, November 2, 1999, XP000938028.	
	5	Anne LACOUR et al., "Comparison of Efficacy and Cost Among Lipid-Lowering Agents in Patients with...", Canadian Journal of Cardiology, Vol. 14, pp. 355-361, March 1998, XP-002156498.	
	6	Takashi OKAMOTO et al., "Caveolins, a Family of Scaffolding Proteins for Organizing...", Journal of Biological Chemistry, Vol. 273, No. 10, pp. 5419-5422, 1998, XP002136663.	
	7	Toyoaki MUROHARA et al., "Nitric Oxide Synthase Modulates Angiogenesis in Response to Tissue Ischemia", Journal of Clinical Investigation, Vol. 11, No. 101, pp. 2567-2578, New York, NY, June 1998, XP002138210.	
	8	Garcia-Cardena GUILLERMO et al., "Dynamic Activation of Endothelial Nitric Oxide Synthase by Hsp90", Nature (London) Vol. 392, No. 6678, pp. 821-824, April 23, 1998, XP002163482.	
	9	Jeffrey B. MICHEL et al., "Reciprocal Regulation of Endothelial NO Synthase by Ca ²⁺ Calmodulin and Caveolin", The Journal of Biological Chemistry, Vol. 272, No. 25, pp. 15583-15586, 1997, XP002136665.	
	10	Jeffrey B. MICHEL et al., "Caveolin versus Calmodulin: Counterbalancing allosteric modulators of endothelial nitric oxide synthase", The Journal of Biological Chemistry, Vol. 272, No. 41, pp. 25907-25912, 1997, XP002136661.	
	11	James KERWIN et al., "The Arginine-Nitric Oxide Pathway: A Target for New Drugs", Medicinal Research Reviews, Vol. 14, No. 1, 1994, pp. 23-74, XP000906832.	
	12	J.S. HANNAH et al., "Effects of Acipimox on the Metabolism of Free Fatty Acids and Very Low density Lipoproteins", Acta Diabetologica, Vol. 32, No. 4, pp. 279-283, 1995, XP-002156499.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. * Applicant is to place a check mark here if English language Translation is attached.

² Reason for Rejection Statement. The form is attached to the communication. The form is attached to the communication.